[Analysis of therapeutic outcomes of polycystic ovary syndrome patients with hyperprolactinemia].
OBJECTIVE
To study effect of drug treatment in polycystic ovary syndrome patients with hyperprolactinemia.


METHODS
We retrospectively studied 63 women with polycystic ovary syndrome and hyperprolactinemia from the Reproductive Medicine Center, Provincial Hospital between January 2005 and March 2007. According to the beginning time of bromocriptine, all women were divided into two groups. Group I was composed of 48 cases who received bromocriptine administration before induction of ovulation cycles, and the dose of bromocriptine was modulated depending on the level of serum prolactin. When serum prolactin was controlled at normal levels, we decreased the dosage of bromocriptine step by step (1.25 mg once), and then continued the treatment at maintenance dosage for no less than 3 weeks. After a baseline ultrasonographic examination on day 3, patients were treated with clomiphene citrate at a dosage of 100 mg (2 tablets/day) for 5 days of a normal cycle or progesterone-induced bleeding. On day 9, we monitored the growth conditions of follicles routinely with trans-vaginal ultrasound. If there was no dominant follicle, we added human menopausal hormone (hMG, 75 U/d) to the protocol. Human chorionic gonadotropin (hCG, 6000-10,000 IU) was given intramuscularly when the mean diameter of a follicle reached at least 18 mm. At the same time we instructed the patients to have sexual intercourses or carried out artificial inseminations before and after ovulation. Group II were 15 cases in which induction of ovulations were commenced almost simultaneously with beginning of bromocriptine. The same protocol was given to patients in group II. The procedures of ovulation induction and the outcomes of treatment were analyzed and compared.


RESULTS
Compared with group II , the days of using hMG in Group I was shorter by instructing the time of sexual intercourse. The difference was significant (P = 0.004). And there were similar results in the artificial insemination cycles (P = 0.009). The rate of pregnancy in group I (40%, 19/48) was higher than that in group II (27%, 4/15), but the difference was not obvious (P = 0.525 ).


CONCLUSIONS
Bromocriptine administration before the stimulated ovulation therapy can decrease the total dosage and treatment course of ovulating drugs. Induction of ovulations simultaneously with start of bromocriptine therapy can shorten the treatment time of infertility.
Shi
Yu-Hua
YH
Reproductive Medicine Center, Provincial Hospital, Affiliated to Shandong University, Jinan 250021, China.
Sheng
Yan
Y
Chen
Zi-Jiang
ZJ
Yan
Jun-Hao
JH
Gao
Qin
Q
Liu
Hong
H
Ma
Zeng-Xiang
ZX
D000328:Adult; D001971:Bromocriptine / Q000008:administration & dosage* / Q000627:therapeutic use; D006063:Chorionic Gonadotropin / Q000008:administration & dosage / Q000627:therapeutic use; D002996:Clomiphene / Q000008:administration & dosage* / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D006966:Hyperprolactinemia / Q000150:complications / Q000188:drug therapy*; D007247:Infertility, Female / Q000188:drug therapy* / Q000209:etiology; D008596:Menotropins / Q000008:administration & dosage / Q000627:therapeutic use; D010062:Ovulation Induction; D011085:Polycystic Ovary Syndrome / Q000150:complications / Q000188:drug therapy*; D011247:Pregnancy; D011388:Prolactin / Q000097:blood; D012189:Retrospective Studies; D016896:Treatment Outcome
D006063:Chorionic Gonadotropin; D002996:Clomiphene; D001971:Bromocriptine; D008596:Menotropins; D011388:Prolactin